

### Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test (Molecular, Conventional), By Infection (UTI, Pneumonia), By Product, By Type, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/HD00369A6E96EN.html

Date: February 2025

Pages: 70

Price: US\$ 5,950.00 (Single User License)

ID: HD00369A6E96EN

#### **Abstracts**

This report can be delivered to the clients within Immediate

Hospital Acquired Infections Diagnostics Market Growth & Trends
The global hospital acquired infections diagnostics market size is expected t%li%reach
USD 4.74 billion by 2030, according t%li%a new report by Grand View Research, Inc.
The global hospital acquired infections diagnostics market is projected t%li%grow at a
healthy CAGR of 1.49% during the period of 2025 t%li%2030. Factors attributing
t%li%the growth of the market are increase in the number of drug-resistant pathogens
such as MRSA and C. difficile, advancing age of geriatric population, and development
of technologically advanced products that offer accurate and reliable results with low
turnaround time.

Another factor contributing t%li%industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely t%li%hinder industry growth.

The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented int%li%Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated t%li%account for the largest share, whereas the pneumonia HAI diagnostics is projected t%li%grow at



the highest CAGR during the period of 2025 t%li%2030. The HAI diagnostics industry is further segmented int%li%molecular tests and other in-vitr%li%tests. Though the molecular diagnostics segment is estimated t%li%constitute a low share, it is anticipated t%li%witness a lucrative growth in the next few years. Hospital Acquired Infections Diagnostics Market Report Highlights

The consumables segment held the largest revenue share in 2024 and is expected t%li%grow at the fastest CAGR of 1.55% over the forecast period,

The blood tests segment held the largest revenue share in 2024 and is expected t%li%grow at the fastest CAGR of 1.55% during the forecast period

Europe dominated the market and accounted for the largest revenue share of 34.57% in 2024, owing t%li%the high disease burden, the availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and the presence of major players.



### **Contents**

#### **CHAPTER 1. METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation & Scope
  - 1.1.1. Test
  - 1.1.2. Infection
  - 1.1.3. Product
  - 1.1.4. Type
  - 1.1.5. Regional scope
  - 1.1.6. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
  - 1.3.1. Purchased database
  - 1.3.2. GVR's internal database
  - 1.3.3. Secondary sources
  - 1.3.4. Primary research
  - 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
  - 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
  - 1.9.1. Objective
  - 1.9.2. Objective

### **CHAPTER 2. EXECUTIVE SUMMARY**

- 2.1. Market Outlook
- 2.2. Segment Outlook
  - 2.2.1. Test outlook
  - 2.2.2. Infection outlook
  - 2.2.3. Product outlook
  - 2.2.4. Type outlook
  - 2.2.5. Regional outlook
- 2.3. Competitive Insights



# CHAPTER 3. HOSPITALS ACQUIRED INFECTIONS DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent market outlook
  - 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
  - 3.3.1. Market driver analysis
  - 3.3.2. Market restraint analysis
- 3.4. Hospitals Acquired Infections Diagnostics Market Analysis Tools
  - 3.4.1. Industry Analysis Porter's
    - 3.4.1.1. Supplier power
    - 3.4.1.2. Buyer power
  - 3.4.1.3. Substitution threat
  - 3.4.1.4. Threat of new entrant
  - 3.4.1.5. Competitive rivalry
  - 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Technological landscape
  - 3.4.2.3. Economic landscape

## CHAPTER 4. HOSPITALS ACQUIRED INFECTIONS DIAGNOSTICS: TEST ESTIMATES & TREND ANALYSIS

- 4.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
- 4.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Conventional
- 4.3.1. Conventional market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Molecular
  - 4.4.1. Molecular market estimates and forecasts, 2018 to 2030 (USD Million)

### CHAPTER 5. HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS: INFECTION ESTIMATES & TREND ANALYSIS

- 5.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
- 5.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030



- 5.3. UTI
  - 5.3.1. UTI market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Pneumonia
  - 5.4.1. Pneumonia market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Surgical Site Infection
- 5.5.1. Surgical site infection market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Blood Stream Infections
- 5.6.1. Blood stream infections market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Others
  - 5.7.1. Others infections market estimates and forecasts, 2018 to 2030 (USD Million)

## CHAPTER 6. HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS: PRODUCT ESTIMATES & TREND ANALYSIS

- 6.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
- 6.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Consumables
  - 6.3.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Instruments
  - 6.4.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)

## CHAPTER 7. HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS

- 7.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
- 7.2. Type Outlook
- 7.2.1. Type Outlook market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.3. Blood Tests
- 7.3.1. Blood tests market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4. Urinalysis
  - 7.4.1. Urinalysis market estimates and forecasts, 2018 to 2030 (USD Million)

# CHAPTER 8. HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

8.1. Regional Outlook



- 8.2. Hospitals Acquired Infections Diagnostics Market by Region: Key Takeaways
- 8.3. North America
  - 8.3.1. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.3.2. U.S.
    - 8.3.2.1. Key Country Dynamics
    - 8.3.2.2. Competitive Scenario
    - 8.3.2.3. Regulatory Framework
    - 8.3.2.4. Reimbursement Scenario
    - 8.3.2.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.3.3. Canada
    - 8.3.3.1. Key Country Dynamics
    - 8.3.3.2. Competitive Scenario
    - 8.3.3.3. Regulatory Framework
    - 8.3.3.4. Reimbursement Scenario
  - 8.3.3.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.3.4. Mexico
    - 8.3.4.1. Key Country Dynamics
    - 8.3.4.2. Competitive Scenario
    - 8.3.4.3. Regulatory Framework
    - 8.3.4.4. Reimbursement Scenario
    - 8.3.4.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4. Europe
  - 8.4.1. UK
    - 8.4.1.1. Key Country Dynamics
    - 8.4.1.2. Competitive Scenario
    - 8.4.1.3. Regulatory Framework
    - 8.4.1.4. Reimbursement Scenario
    - 8.4.1.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.4.2. Germany
    - 8.4.2.1. Key Country Dynamics
    - 8.4.2.2. Competitive Scenario
    - 8.4.2.3. Regulatory Framework
    - 8.4.2.4. Reimbursement Scenario
    - 8.4.2.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.4.3. France
    - 8.4.3.1. Key Country Dynamics
    - 8.4.3.2. Competitive Scenario
    - 8.4.3.3. Regulatory Framework
    - 8.4.3.4. Reimbursement Scenario



- 8.4.3.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4.4. Italy
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Scenario
  - 8.4.4.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4.5. Spain
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Competitive Scenario
  - 8.4.5.3. Regulatory Framework
- 8.4.5.4. Reimbursement Scenario
- 8.4.5.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4.6. Denmark
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Competitive Scenario
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Reimbursement Scenario
- 8.4.6.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4.7. Sweden
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Competitive Scenario
  - 8.4.7.3. Regulatory Framework
  - 8.4.7.4. Reimbursement Scenario
- 8.4.7.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.4.8. Norway
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Competitive Scenario
  - 8.4.8.3. Regulatory Framework
  - 8.4.8.4. Reimbursement Scenario
  - 8.4.8.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.5. Asia Pacific
  - 8.5.1. Japan
    - 8.5.1.1. Key Country Dynamics
    - 8.5.1.2. Competitive Scenario
    - 8.5.1.3. Regulatory Framework
    - 8.5.1.4. Reimbursement Scenario
  - 8.5.1.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.5.2. China



- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Scenario
- 8.5.2.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.5.3. India
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Scenario
  - 8.5.3.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Competitive Scenario
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Scenario
- 8.5.4.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.5.5. Thailand
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Competitive Scenario
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Scenario
- 8.5.5.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.5.6. South Korea
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Scenario
- 8.5.6.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.6. Latin America
  - 8.6.1. Brazil
    - 8.6.1.1. Key Country Dynamics
    - 8.6.1.2. Competitive Scenario
    - 8.6.1.3. Regulatory Framework
    - 8.6.1.4. Reimbursement Scenario
    - 8.6.1.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
  - 8.6.2. Argentina
    - 8.6.2.1. Key Country Dynamics
    - 8.6.2.2. Competitive Scenario



- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Scenario
- 8.6.2.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)

#### 8.7. MEA

- 8.7.1. South Africa
- 8.7.1.1. Key Country Dynamics
- 8.7.1.2. Competitive Scenario
- 8.7.1.3. Regulatory Framework
- 8.7.1.4. Reimbursement Scenario
- 8.7.1.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Scenario
- 8.7.2.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Scenario
- 8.7.3.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)
- 8.7.4. Kuwait
  - 8.7.4.1. Key Country Dynamics
  - 8.7.4.2. Competitive Scenario
  - 8.7.4.3. Regulatory Framework
  - 8.7.4.4. Reimbursement Scenario
  - 8.7.4.5. Market estimates and forecasts, 2018 2030 (Revenue, USD Million)

#### **CHAPTER 9. COMPETITIVE LANDSCAPE**

- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Company Market Share Analysis, 2024
- 9.4. Company Profiles
  - 9.4.1. BIOM?RIEUX
    - 9.4.1.1. Company overview
    - 9.4.1.2. Financial performance
    - 9.4.1.3. Product benchmarking



- 9.4.1.4. Strategic initiatives
- 9.4.2. Abbott
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. F. Hoffmann-La Roche Ltd
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. Siemens Healthcare Private Limited
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. BD (Becton, Dickinson and Company)
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. Hologic, Inc.
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. Meridian Bioscience, Inc.
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. QIAGEN
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. Thermo Fisher Scientific Inc.
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance



- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Bioscience, Inc.
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives



#### I would like to order

Product name: Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By

Test (Molecular, Conventional), By Infection (UTI, Pneumonia), By Product, By Type, By

Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/HD00369A6E96EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/HD00369A6E96EN.html">https://marketpublishers.com/r/HD00369A6E96EN.html</a>